{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"211"}]}],"title":"1 day"},{"categories":[{"measurements":[{"groupId":"OG000","value":"339"}]}],"title":"2 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"729"}]}],"title":"3 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"422"}]}],"title":"4 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2718"}]}],"title":"5 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"385"}]}],"title":"6 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"682"}]}],"title":"7 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"115"}]}],"title":"8 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"}]}],"title":"9 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"120"}]}],"title":"10 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"11 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"12 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"13 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"105"}]}],"title":"14 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}],"title":">=15 days"}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"1447"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"5942"}],"units":"cycles"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"All cycles from patients in the evaluable sample with study drug duration","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"EP2006 Cycles by Treatment Duration","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"cycles"}